Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone

BACKGROUND: Use of azathioprine (AZA) for inflammatory bowel disease is limited by side effects or poor efficacy. Combining low-dose azathioprine with allopurinol (LDAA) bypasses side effects, improves efficacy, and may be appropriate as first-line therapy. We test the hypothesis that standard-dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Coulthard, Sally A., Berry, Phil, McGarrity, Sarah, McLaughlin, Simon, Ansari, Azhar, Redfern, Christopher P. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Basic Science Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436732/
https://www.ncbi.nlm.nih.gov/pubmed/28452864
http://dx.doi.org/10.1097/MIB.0000000000001131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436732/
https://www.ncbi.nlm.nih.gov/pubmed/28452864
http://dx.doi.org/10.1097/MIB.0000000000001131

Ejemplares similares